Abstract:Purpose: Voriconazole (VOR) is combined with atorvastatin (ATO) to treat fungal infections in patients with dyslipidemia in clinical practice. However, the pharmacokinetic interactions and potential mechanisms between them are unknown. Therefore, this study aimed to investigate the pharmacokinetic interactions and potential mechanisms between ATO and VOR. Patients and methods: We collected plasma samples from three patients using ATO and VOR. Rats were administered either VOR or normal saline for 6 days, followed by a single dose of 2 mg/kg ATO, and then plasma samples were collected at different time points. The incubation models of human liver microsomes or HepG2 cells were constructed in vitro . A high-performance liquid chromatography-tandem mass spectrometry (HPLC-MS/MS) system was developed to determine the concentration of ATO, 2-hydroxy-ATO, 4-hydroxy-ATO, and VOR. Results: In patients, VOR significantly reduced the metabolism of ATO and slowed the formation of 2-hydroxy- and 4-hydroxy-ATO. In rats pretreated with orally administered VOR for 6 days or normal saline given a single dose of 2 mg/kg ATO administered orally on Day 6, the t 1/2 of ATO was significantly prolonged from 3.61 to 6.43 h, and the area under the concentration-time curve (AUC 0–24h ) values of ATO increased from 53.86 to 176.84 h μg.L −1 . However, the pharmacokinetic parameters of VOR (20 mg/kg) with or without pretreatment with ATO (2 mg/kg) only slightly changed. In vitro studies indicated that VOR inhibited the metabolism of ATO and testosterone, and the IC 50 values were 45.94 and 49.81 μM. However, no significant change in transporter behaviors of ATO was observed when VOR or transporter inhibitors were co-administered. Conclusion: Our study demonstrated that VOR has significant interactions with ATO, probably due to VOR's inhibition of the CYP3A4-mediated metabolism of ATO. Based on the clinical cases and potential interactions, the basic data obtained in our study are expected to help adjust the dose of ATO and promote the design of rational dosage regimens for pharmacotherapy for fungal infections in patients with dyslipidemia.

Bioavailability of Vitexin-2"-O-rhamnoside after Oral Co-administration with Ketoconazole, Verapamil and Bile Salts

Hepatic, Gastric and Intestinal First-Pass Effects of Vitexin-2-O-Rhamnoside in Rats by Ultra-High-Performance Liquid Chromatography

Hepatic and gastrointestinal first-pass effects of vitexin-4″-O-glucoside in rats.

HPLC Determination of Vitexin-2"-o-rhamnoside Concentration in Rat Plasma and Its Pharmacokinetic Study

Comparative Excretion of Vitexin-2"-o-rhamnoside in Mice after Oral and Intravenous Administration

Tissue distribution and pharmacokinetics of vitexin-2'-O-rhamnoside in mice after oral and intravenous administration

Hepatic, gastric, and intestinal first-pass effects of vitexin in rats

LC Determination and Pharmacokinetic Study of Vitexin-4″-o-glucoside in Rat Plasma after Oral Administration

Effect of Cytochrome P-450 Inhibitors on Pharmacokinetics and Safety of Voriconazole

UHPLC method for simultaneous assessment of pharmacokinetic parameters of co-administered voriconazole and omeprazole using rat plasma

Pharmacokinetics of Vitexin in Rats

Quantitative LC/MS/MS Method and in Vivo Pharmacokinetic Studies of Vitexin Rhamnoside, a Bioactive Constituent on Cardiovascular System from Hawthorn.

Distribution, Metabolism, Excretion and Toxicokinetics of Vitexin in Rats and Dogs

Interaction and potential mechanisms between atorvastatin and voriconazole, agents used to treat dyslipidemia and fungal infections

Pharmacokinetics of Vitexin-4″-o-glucoside in Rats after Intravenous Application

Evaluation of the Effects of Ketoconazole and Voriconazole on the Pharmacokinetics of Oxcarbazepine and Its Main Metabolite MHD in Rats by UPLC-MS-MS.

Hplc Determination Of Vitexin-4 ''-O-Glucoside In Mouse Plasma And Tissues After Oral And Intravenous Administration

Simultaneous Determination of Vitexin Rhamnoside and Vitexin Glucoside in Rats by Liquid Chromatography Coupled with Mass Spectrometry

Determination of Voriconazole and Relative Bioavailability in Human Plasma by HPLC-MS/MS

Enhancement of Absorption and Bioavailability of Echinacoside by Verapamil or Clove Oil

Preparation of Vitexin Albumin Nanoparticles and Its Pharmacokinetic Study